Reported 4 months ago
Portfolio manager Cathie Wood is buying the dip on two biotech stocks, CRISPR Therapeutics and Intellia Therapeutics. CRISPR Therapeutics, down 13% this year, specializes in gene therapy with strong growth potential. Intellia Therapeutics, down 27% this year, is working on a rare genetic illness treatment, but may face financial challenges. While these stocks offer significant upside, they are volatile and risky investments, especially for those with lower risk tolerance.
Source: YAHOO